Fennec Pharmaceuticals Valuation
Is RV41 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RV41 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RV41 (€5.95) is trading below our estimate of fair value (€254.94)
Significantly Below Fair Value: RV41 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RV41?
Other financial metrics that can be useful for relative valuation.
| What is RV41's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$175.42m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does RV41's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14x | ||
2INV 2invest | 33.7x | n/a | €53.2m |
FYB Formycon | 12.2x | 20.3% | €923.6m |
BIO3 Biotest | 6x | -75.0% | €1.3b |
93M1 MPH Health Care | 4.2x | 8.4% | €123.3m |
RV41 Fennec Pharmaceuticals | 61.7x | 46.1% | €175.4m |
Price-To-Earnings vs Peers: RV41 is expensive based on its Price-To-Earnings Ratio (61.7x) compared to the peer average (14x).
Price to Earnings Ratio vs Industry
How does RV41's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: RV41 is expensive based on its Price-To-Earnings Ratio (61.7x) compared to the European Biotechs industry average (27.7x).
Price to Earnings Ratio vs Fair Ratio
What is RV41's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 61.7x |
| Fair PE Ratio | 22.3x |
Price-To-Earnings vs Fair Ratio: RV41 is expensive based on its Price-To-Earnings Ratio (61.7x) compared to the estimated Fair Price-To-Earnings Ratio (22.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €5.95 | €15.64 +162.9% | 15.1% | €20.44 | €13.01 | n/a | 6 |
| Jun ’25 | €6.15 | €15.47 +151.5% | 15.1% | €20.22 | €12.87 | n/a | 6 |
| May ’25 | €8.30 | €16.91 +103.8% | 11.6% | €20.30 | €14.76 | n/a | 6 |
| Apr ’25 | €10.20 | €16.84 +65.1% | 12.1% | €20.39 | €14.83 | n/a | 6 |
| Mar ’25 | €8.55 | €15.09 +76.5% | 3.0% | €15.64 | €14.72 | n/a | 5 |
| Feb ’25 | €9.00 | €15.09 +67.6% | 3.0% | €15.64 | €14.72 | n/a | 5 |
| Jan ’25 | €10.20 | €15.12 +48.2% | 4.3% | €15.90 | €14.03 | n/a | 6 |
| Dec ’24 | €7.65 | €15.12 +97.6% | 4.3% | €15.90 | €14.03 | n/a | 6 |
| Nov ’24 | €6.30 | €14.69 +133.2% | 4.3% | €15.45 | €13.63 | n/a | 6 |
| Oct ’24 | €6.60 | €14.69 +122.6% | 4.3% | €15.45 | €13.63 | n/a | 6 |
| Sep ’24 | €7.30 | €14.69 +101.2% | 4.3% | €15.45 | €13.63 | n/a | 6 |
| Aug ’24 | €7.85 | €14.87 +89.4% | 5.8% | €16.39 | €13.65 | n/a | 6 |
| Jul ’24 | €7.95 | €14.87 +87.0% | 5.8% | €16.39 | €13.65 | n/a | 6 |
| Jun ’24 | €6.90 | €14.95 +116.7% | 5.8% | €16.48 | €13.73 | €6.15 | 6 |
| May ’24 | €7.55 | €14.95 +98.1% | 5.8% | €16.48 | €13.73 | €8.30 | 6 |
| Apr ’24 | €7.65 | €14.36 +87.8% | 12.0% | €16.50 | €11.00 | €10.20 | 6 |
| Mar ’24 | €8.30 | €14.51 +74.8% | 12.3% | €16.50 | €11.00 | €8.55 | 6 |
| Feb ’24 | €8.95 | €14.51 +62.1% | 12.3% | €16.50 | €11.00 | €9.00 | 6 |
| Jan ’24 | €8.85 | €15.78 +78.3% | 14.0% | €18.55 | €11.71 | €10.20 | 6 |
| Dec ’23 | €9.10 | €15.78 +73.4% | 14.0% | €18.55 | €11.71 | €7.65 | 6 |
| Nov ’23 | €8.65 | €16.01 +85.1% | 20.7% | €19.42 | €9.20 | €6.30 | 6 |
| Oct ’23 | €7.95 | €14.49 +82.2% | 26.1% | €19.39 | €9.18 | €6.60 | 5 |
| Sep ’23 | €6.80 | €10.25 +50.7% | 26.9% | €13.45 | €6.72 | €7.30 | 3 |
| Aug ’23 | €6.45 | €10.25 +58.9% | 26.9% | €13.45 | €6.72 | €7.85 | 3 |
| Jul ’23 | €5.15 | €10.25 +99.0% | 26.9% | €13.45 | €6.72 | €7.95 | 3 |
| Jun ’23 | €5.15 | €9.96 +93.3% | 23.8% | €13.28 | €6.64 | €6.90 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.